论文部分内容阅读
采用免疫组织化学方法对１９９５年～１９９７年完成的３６０例甲状腺癌、腺瘤及结节性甲状腺肿的切除标本进行雌激素受体（ＥＲ）和孕激素受体（ＰｇＲ）检测，探讨女性激素在甲状腺癌的发生过程中所起的作用。结果显示甲状腺癌、腺瘤及结节性甲状腺肿的病变组织中，多可查见例数不等和含量不同的女性激素受体，其中甲状腺癌的ＥＲ、ＰｇＲ阳性表达（５９．０％、６６．７％）明显高于结节性甲状腺肿和腺瘤（３４．０％、２５．９％，Ｐ＜０．０５，Ｐ＜０．０１）；分化型癌尤其是乳头状癌ＥＲ、ＰｇＲ表达最高为７３．１％和８０．８％。结果提示，女性激素是甲状腺分化型癌的重要诱发因素，ＥＲ、ＰｇＲ检测有可能成为判断癌组织分化及估计预后的一项新的参考指标
Immunohistochemistry was used to detect estrogen receptor (ER) and progesterone receptor (PgR) in the resection specimens of 360 cases of thyroid cancer, adenoma, and nodular goiter completed from 1995 to 1997. Role in the development of thyroid cancer. The results showed that thyroid cancer, adenoma and nodular goiter in the lesions, can be found in the number of cases and the content of different female hormone receptors, including thyroid cancer ER, PgR positive expression (59.0%, 66.7%) was significantly higher than nodular goiter and adenoma (34.0%, 25.9%, P<0.05, P<0.01); differentiated carcinoma, especially papillary carcinoma ER, The highest expression of PgR was 73.1% and 80.8%. The results suggest that female hormone is an important predisposing factor for differentiated thyroid cancer, and detection of ER and PgR may become a new reference for judging differentiation and estimating prognosis of cancer tissues.